Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

Human epidermal growth factor receptor 2–positive (HER2+) breast cancer accounts for~
25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to …

In this Phase I trial, patients' peripheral blood dendritic cells were pulsed with peptides
eluted from the surface of autologous glioma cells. Three biweekly intradermal vaccinations …

Purpose: Patients with malignant glioma suffer global compromise of their cellular immunity,
characterized by dramatic reductions in CD4+ T cell numbers and function. We have …

Recent studies have shown that the brain is not a barrier to successful active
immunotherapy that uses gene-modified autologous tumor cell vaccines. In this study, we …

The crafting of genetic and biochemical techniques to identify cancer antigens yielded the
unexpected discovery that immune recognition of tumors regularly accompanies cancer …

Purpose: To investigate the safety and the immunologic and clinical responses of dendritic
cell therapy for patients with recurrent malignant glioma. Experimental Design: Twenty-four …

In the year 2000, an estimated 1220100 new cases of invasive cancer will be diagnosed in
the United States, and about 552 200 people are expected to die of it (Greenlee et al. 2000) …

Glioblastoma patients are immunosuppressed, yet glioblastomas are highly infiltrated by
monocytes/macrophages. Myeloid-derived suppressor cells (MDSC; immunosuppressive …

Abstract In this Phase I/II trial, the patient's peripheral blood dendritic cells were pulsed with
an autologous tumour lysate of the glioma. Seven patients with glioblastoma and three …